Shire posts better-than-expected 13 percent rise in fourth-quarter earnings

Shire , the London-listed drugmaker buying Baxalta International for $32 billion, reported a better-than-expected 13 percent rise in fourth-quarter earnings on Thursday, helped by strong sales of its ADHD treatment Vyvanse. Chief Executive Flemming Ornskov said the deal, which is forecast to close mid-2016, would make Shire the leading company in rare diseases and propel annual sales to more than $20 billion by 2020. For the fourth quarter, Shire reported non-GAAP earnings per share of $2.97 on